Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Trial registration: ClinicalTrials.gov number: NCT01777152

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood cancer journal (New York) Ročník 15; číslo 1; s. 129 - 5
Hlavní autoři: Domingo-Domènech, Eva, Pro, Barbara, Illidge, Tim, Horwitz, Steven, Trumper, Lorenz, Iyer, Swami, Advani, Ranjana, Bartlett, Nancy L., Christensen, Jacob Haaber, Kim, Won-Seog, Feldman, Tatyana, Choi, Ilseung, Gritti, Giuseppe, Belada, David, Shustov, Andrei, Illes, Arpad, Zinzani, Pier Luigi, Hüttmann, Andreas, Trneny, Marek, Le Gouill, Steven, Jagadeesh, Deepa, Friedberg, Jonathan W., Little, Meredith, Dong, Cassie, Fanale, Michelle, Fenton, Keenan, Savage, Kerry J.
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 01.08.2025
Springer Nature B.V
Nature Publishing Group
Témata:
692/308/153
692/699/67/1990/291/1621/1916
692/700/565/1436/2185
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomedical and Life Sciences
Biomedicine
Brentuximab Vedotin - administration & dosage
Brentuximab Vedotin - adverse effects
Brentuximab Vedotin - therapeutic use
Cancer Research
Chemotherapy
Confidence intervals
Correspondence
Female
Follow-Up Studies
Hematology
Humans
Kinases
Lymphoma
Lymphoma, Large-Cell, Anaplastic - drug therapy
Lymphoma, Large-Cell, Anaplastic - mortality
Lymphoma, Large-Cell, Anaplastic - pathology
Male
Medical prognosis
Middle Aged
Oncology
Remission (Medicine)
Treatment Outcome
ISSN:2044-5385, 2044-5385
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Trial registration: ClinicalTrials.gov number: NCT01777152
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Correspondence-3
content type line 23
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-025-01329-2